SurModics Announces Agreement to Sell Pharmaceutical Assets for $30M
Courtesy of Benzinga.
SurModics, Inc. (Nasdaq: SRDX) announced last night that it has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to Evonik Industries AG for $30 million in cash. Under the Asset Purchase Agreement, the entire portfolio of products and services of SurModics Pharmaceuticals, including the Company’s cGMP development and manufacturing facility located in Birmingham, Alabama, will be acquired by Evonik.
This grants Evonik ownership of SurModics’ parenteral dosage technology platforms and services and bioresorbable lactide-glycolide polymers business.
Do you know someone
who would benefit from this
information? We can send your friend a strictly
confidential, one-time email telling them about this
information. Your privacy and your friend's privacy is
your business... no spam! Click here
and tell a friend!

Facebook
Twitter
LinkedIn
del.icio.us
Digg